Anavex Life Sciences Corp. (NASDAQ:AVXL) has earned an average recommendation of “Buy” from the six brokerages that are currently covering the company, Marketbeat.com reports. One analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $17.60.
Several equities analysts recently weighed in on AVXL shares. LADENBURG THALM/SH SH reaffirmed a “buy” rating and set a $20.00 target price on shares of Anavex Life Sciences in a research note on Wednesday, February 17th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $25.00 price target (up from $10.00) on shares of Anavex Life Sciences in a report on Monday, March 1st. Finally, Zacks Investment Research lowered shares of Anavex Life Sciences from a “buy” rating to a “hold” rating in a report on Friday, February 12th.
In other news, Director Elliot Favus sold 145,500 shares of the company’s stock in a transaction dated Wednesday, February 24th. The stock was sold at an average price of $12.66, for a total transaction of $1,842,030.00. Following the completion of the transaction, the director now directly owns 45,000 shares of the company’s stock, valued at approximately $569,700. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 12.40% of the stock is currently owned by company insiders.
Shares of NASDAQ:AVXL traded down $0.19 during midday trading on Wednesday, reaching $11.61. The company’s stock had a trading volume of 883,200 shares, compared to its average volume of 3,647,262. Anavex Life Sciences has a 12-month low of $3.01 and a 12-month high of $28.70. The firm has a 50 day moving average of $14.06 and a 200-day moving average of $8.39. The firm has a market capitalization of $813.06 million, a P/E ratio of -26.22 and a beta of 0.70.
Anavex Life Sciences (NASDAQ:AVXL) last released its quarterly earnings data on Wednesday, February 10th. The biotechnology company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.01). As a group, analysts predict that Anavex Life Sciences will post -0.46 EPS for the current fiscal year.
About Anavex Life Sciences
Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer’s and Parkinson’s disease and central nervous system diseases, including Rett syndrome.
Further Reading: Why is the ROA ratio important?
Receive News & Ratings for Anavex Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anavex Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.